Gilead Sciences wants first dibs on all Assembly Biosciences’ programs. Rather than buy the viral disease biotech outright, Gilead is paying $100 million upfront for opt-in rights on all Assembly ...
Gilead (GILD) and Assembly Biosciences (ASMB), announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes ...
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its ...
Assembly Biosciences, Inc. reported progress in its clinical development of antiviral candidates, with data from multiple programs expected in 2025. Specifically, interim Phase 1b data for long-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback